PROCESS VALIDATION - ACTUAL REGULATION, PERFORMING AND INSPECTION

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Workshop on SPS Coordination 17 October 2011 Codex Alimentarius Commission Standard-setting Procedures Selma H. Doyran Joint FAO/WHO Food Standards Programme.
© WHO – PSM Validations – part 1 Workshop on GMP and Quality Assurance of TB products Kuala Lumpur Malaysia, 21 – 25 February 2005 Maija Hietava M.Sci.Pharm.
The New GMP Annex 11 and Chapter 4 Deadline for coming into operation: 30 June 2011.
ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Validation Part 2: Cleaning validation
Define ● Deliver ● Sustain Sundar Chellamani Technical Director SysComm Project Management Ltd.
Validation.
Validation SAPRAA March 2013.
World Health Organization
WHO Supplementary Training Modules GMP
Regulatory requirements and benefits converting to Continued Process Verification.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
RPS WG Update March 2015 Open Stakeholder Session Nancy Shadeed Health Canada.
Module 1, Part 1: Introduction and The VMP Slide 1 of 22 © WHO – EDM Validation Supplementary Training Modules on Good Manufacturing Practices.
Radiopharmaceutical Production
European Directorate for the Quality of Medicines & health care (EDQM)
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
Basic Principles of GMP
1 Manufacturing Processes and Validation for Next Generation Implants.
VALIDATION METHODOLOGY
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
PRODUCT TRANSFER.
© Pharmaceutical Consultancy Services, All rights reserved. PROCESS VALIDATION Jaap Koster.
And Pharmaceuticals Health Technology Technical Cooperation for Essential Drugs and Traditional Medicine Challenges of Medicine Regulation in Africa Global.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
Important informations
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.
Molecule-to-Market-Place Quality
Joel Gerber Zachary Reaver Kurt Schilling.  Provides physical proof of development  Maintains product design knowledge base  Meets government and corporate.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September 2010 Selection of comparators Compiled by Jan Welink WHO Workshop.
Project Management Workshop Carmen B. Jacobs, RN,OCN, CCRP Office of Multicenter Clinical Research.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Module 4Slide 1 of 23 WHO - EDM Validation Basic Principles of GMP.
Sterile product validation
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Training Session Product File Notes and Registration Reports, 23 October Registration Report Part Residues Frédéric Joris and Bruno Dujardin Federal.
1 Manufacturing Processes and Validation for Next Generation Implants.
© Pharmaceutical Consultancy Services, All rights reserved. Process Validation (based on FDA guide)
Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.
CONVALIDA E QUALIFICA: I NUOVI ORIENTAMENTI DELL’ANNEX 15 Anna Fumagalli Labochim 19 aprile 2016.
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Drug Utilization Review & Drug Utilization Evaluation: An Overview
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
World Health Organization
Pharmaceutical Quality Control & current Good Manufacturing Practice
An Update on ICH Guideline – Pharmaceutical Development
ICH-GCP Avinash Kondawar M. Pharm Lead CRA
Data Managers’ Forum What’s in it for us?
Quality Risk Management
II. 6 Quality risk management as part of…
QUALITY MANAGEMENT SYSTEM
Joint WG on Guidance for an Integrated Transport and Storage Safety Case for Dual Purpose Casks TM TM to Produce Consolidated Drafts of the IAEA’s.
Harmonization for Patient Centered Universal Health Coverage
ICH Q9: Quality Risk Management
ICH Q9: Quality Risk Management
Analytical Method Validation PAI Readiness / Certification
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Impact statement Annex 1
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Manufacture of Sterile Medicinal Products: ‘Annex 1’ - DRAFT
SID & GP MINPROMTORG OF RUSSIA Corporate Communication Center
Presentation transcript:

PROCESS VALIDATION - ACTUAL REGULATION, PERFORMING AND INSPECTION

Eurasian Economic Commission​​ decision № 77 new revision Annex 15 harmonization with EMA regulation Main idea: inclusion of the principles of ICH (Q8, Q9, Q10) in Annex 15. ICH Q8 Pharmaceutical Development ICH Q10 Pharmaceutical Quality System ICH Q9 Quality Risk Management Knowledge management Design space Risk-based approaches

Eurasian Economic Commission​​ decision № 77 new revision Key changes in Annex 15: Documentation Qualification Process and Cleaning Validation New sections: Ongoing Process Verification during Lifecycle Verification of Transportation Validation of Packaging Qualification of Utilities Validation of Test Methods Planning and documentation for Qualification and Validation Added information on the qualification stages Major revision of the Process and Cleaning Validation sections

Manufacturing process validation Cleaning Validation Harmonization with Eurasian Economic Commission​​ decision № 19 Toxicological evaluation Prospective validation Traditional approach Appropriate number of times based on a risk assessment Continuous Process Verification Hybrid Approach Concurrent validation Where there is strong risk – benefit to the patient Retrospective validation? Not acceptable!

Deficiencies There are no manufacturing process validation or cleaning validation. There are no justification for concurrent process validation approach. There are no justification for CPP’s. The evaluation of the risk to quality is not based on scientific knowledge, experience with the process. Cleaning validation was performed with out toxicological evaluation.

Deficiencies Cleaning validation was performed with out microbiological or bacterial endotoxins consideration. There are no drug product testing results in manufacturing process validation report. Less than three consecutive batches were manufactured during manufacturing process validation. There are no results for few acceptance criteria mentioned in validation protocol.

Thank you! QUESTIONS PLEASE!